跳转至内容
Merck
所有图片(1)

主要文件

565788

Sigma-Aldrich

β-分泌酶抑制剂 IV

≥98% (HPLC), solid, β-secretase inhibitor, Calbiochem®

别名:

β-分泌酶抑制剂 IV

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C31H38N4O5S
CAS号:
797035-11-1
分子量:
578.72
MDL编号:
MFCD09037559
UNSPSC代码:
12352200
NACRES:
NA.77
价格与库存信息目前不能提供

产品名称

β-分泌酶抑制剂 IV, β-Secretase Inhibitor IV, CAS 797035-11-1, is a cell-permeable inhibitor that binds to BACE-1 active site and blocks its proteolytic activity (IC₅₀ = 15 nM for human BACE-1).

质量水平

100

方案

≥98% (HPLC)

表单

solid

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
protect from light

颜色

white

溶解性

DMSO: 100 mg/mL

运输

ambient

储存温度

2-8°C

SMILES字符串

[S](=O)(=O)(N(C)c1cc(cc(c1)C(=O)N[C@H](C)c4ccccc4)C(=O)N[C@H]([C@H](O)CNC3CC3)Cc2ccccc2)C

InChI

1S/C31H38N4O5S/c1-21(23-12-8-5-9-13-23)33-30(37)24-17-25(19-27(18-24)35(2)41(3,39)40)31(38)34-28(16-22-10-6-4-7-11-22)29(36)20-32-26-14-15-26/h4-13,17-19,21,26,28-29,32,36H,14-16,20H2,1-3H3,(H,33,37)(H,34,38)/t21-,28+,29-/m1/s1

InChI key

VPNIQGRFZCTBEZ-SPTGULJVSA-N

一般描述

一种细胞渗透性间苯二甲酰胺化合物，含有羟乙基胺基序，与BACE-1活性位点结合并能有效阻断其蛋白水解活性（BACE-1，人的IC50 = 15 nM，在HEK293-APPAPPNFEV细胞中sAPP_NF的IC50=29 nM）。显示出比其他天冬氨酰蛋白酶更高的选择性（BACE-2、组织蛋白酶D和肾素的IC50分别为0.23 µM、7.6 µM和>50 µM）。也可提供10 mM的DMSO溶液（目录号565794）。

请注意，由于水含量的变化，该化合物的分子量因批次而异。

生化/生理作用

主靶
BACE-1人
产物不与ATP竞争。
可逆：否
细胞可渗透性：是
靶标IC50：BACE-1，人为15 nM，在HEK293-APPNFEV细胞中的sAPP_NF为29 nM

包装

用惰性气体包装

警告

毒性：标准处理（A）

重悬

复溶后，等分并冷冻保存（-20°C）。贮备溶液在-20°C下可稳定保存至多3个月。

其他说明

Halima, S.B., et al. 2016.Cell Reports.14, In press.
Stachel, S.J., et al. 2004.J. Med. Chem.47, 6447.
在DMSO（10 mg/ml）中溶解，等分&贮藏在-20℃下；可稳定3个月。

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

储存分类代码

11 - Combustible Solids

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Yuji Kamikubo et al.
Frontiers in molecular neuroscience, 15, 1068990-1068990 (2023-01-24)
Alzheimer's disease (AD) is a progressive neurodegenerative brain disorder and the most common cause of dementia in the elderly. The presence of large numbers of senile plaques, neurofibrillary tangles, and cerebral atrophy is the characteristic feature of AD. Amyloid β
Noa Stern et al.
International journal of molecular sciences, 23(21) (2022-11-12)
Alzheimer's disease (AD) is a complex and widespread condition, still not fully understood and with no cure yet. Amyloid beta (Aβ) peptide is suspected to be a major cause of AD, and therefore, simultaneously blocking its formation and aggregation by
Christiane Volbracht et al.
Analytical biochemistry, 387(2), 208-220 (2009-05-21)
Amyloid-beta peptide (Abeta), a putatively causative agent of Alzheimer's disease (AD), is proteolytically derived from beta-amyloid precursor protein (APP). Here we describe cellular assays to detect the activity of the key protease beta-site of APP cleaving enzyme 1 (BACE1) based
Hirotaka Watanabe et al.
Methods in molecular biology (Clifton, N.J.), 2549, 209-217 (2021-05-08)
Amyloid β (Aβ) peptides are the main component of the characteristic insoluble deposits in brain parenchyma and small blood vessels in the patients afflicted with Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA). These small peptides are attributed to the
Helen A Rowland et al.
Neuronal signaling, 7(4), NS20230016-NS20230016 (2023-10-09)
Alzheimer's disease (AD) is characterised by the aggregation and deposition of amyloid-β (Aβ) peptides in the human brain. In age-related late-onset AD, deficient degradation and clearance, rather than enhanced production, of Aβ contributes to disease pathology. In the present study
查看所有相关文献

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门